JP2016539629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539629A5 JP2016539629A5 JP2016524423A JP2016524423A JP2016539629A5 JP 2016539629 A5 JP2016539629 A5 JP 2016539629A5 JP 2016524423 A JP2016524423 A JP 2016524423A JP 2016524423 A JP2016524423 A JP 2016524423A JP 2016539629 A5 JP2016539629 A5 JP 2016539629A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- ltr
- vector according
- optional
- retroviral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001177 retroviral effect Effects 0.000 claims 16
- 238000004806 packaging method and process Methods 0.000 claims 12
- 210000002845 virion Anatomy 0.000 claims 8
- 238000000034 method Methods 0.000 claims 4
- 108700019146 Transgenes Proteins 0.000 claims 3
- 238000001415 gene therapy Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000010839 reverse transcription Methods 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091027981 Response element Proteins 0.000 claims 1
- 108700009124 Transcription Initiation Site Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 230000001124 posttranscriptional effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1318347.0 | 2013-10-16 | ||
| GBGB1318347.0A GB201318347D0 (en) | 2013-10-16 | 2013-10-16 | Retroviral vectors |
| PCT/GB2014/053102 WO2015056014A1 (en) | 2013-10-16 | 2014-10-16 | Retroviral vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539629A JP2016539629A (ja) | 2016-12-22 |
| JP2016539629A5 true JP2016539629A5 (OSRAM) | 2017-11-24 |
| JP6525986B2 JP6525986B2 (ja) | 2019-06-05 |
Family
ID=49680159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524423A Active JP6525986B2 (ja) | 2013-10-16 | 2014-10-16 | レトロウイルスベクター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10184136B2 (OSRAM) |
| EP (1) | EP3058076B1 (OSRAM) |
| JP (1) | JP6525986B2 (OSRAM) |
| CN (1) | CN105705645B (OSRAM) |
| ES (1) | ES2759049T3 (OSRAM) |
| GB (1) | GB201318347D0 (OSRAM) |
| WO (1) | WO2015056014A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| AU2017254665C1 (en) | 2016-04-20 | 2021-03-11 | Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. | Compositions and methods for enhanced gene expression of PKLR |
| SG11201901718VA (en) * | 2016-09-08 | 2019-03-28 | Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas | Gene therapy for patients with fanconi anemia |
| EP3672617A4 (en) * | 2017-08-22 | 2021-06-23 | The Regents of the University of California | LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES |
| BR112020007444A2 (pt) | 2017-10-16 | 2020-10-20 | Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. | vetores lentivirais para a liberação de pklr para tratar deficiência de piruvato quinase |
| BR112020021903A2 (pt) | 2018-04-27 | 2021-03-02 | Rocket Pharmaceuticals, Ltd. | terapia genética para degeneração do snc |
| CN108676815A (zh) * | 2018-05-31 | 2018-10-19 | 深圳市免疫基因治疗研究院 | 一种b型血友病慢病毒载体、慢病毒及其制备方法和应用 |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| EP3983538A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN116194154A (zh) | 2020-08-07 | 2023-05-30 | 太空飞船七有限责任公司 | 使用aav载体的plakophilin-2(pkp2)基因疗法 |
| GB202019084D0 (en) * | 2020-12-03 | 2021-01-20 | Ucl Business Ltd | Retroviral vectors |
| WO2022159799A1 (en) * | 2021-01-25 | 2022-07-28 | Prevail Therapeutics, Inc. | Modulation of aav-based gene expression |
| EP4362957A1 (en) | 2021-07-01 | 2024-05-08 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN114931652B (zh) * | 2022-06-23 | 2024-01-26 | 中国人民解放军陆军军医大学第一附属医院 | 一种Hmga2基因在修复受损视网膜中的应用 |
| CA3259982A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics Inc | COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| GB202306491D0 (en) | 2023-05-03 | 2023-06-14 | Ucl Business Ltd | Retroviral vectors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707091B1 (fr) * | 1993-06-30 | 1997-04-04 | Cohen Haguenauer Odile | Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes. |
| US5714353A (en) * | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| FR2751345B1 (fr) | 1996-07-16 | 1998-09-18 | Univ Paris Curie | Lignees d'encapsidation hautement productrices |
| US20050266544A1 (en) | 1999-04-30 | 2005-12-01 | Human Gene Therapy Research Institute | Methods and compositions for increasing viral vector production in packaging cell lines |
| US8158413B2 (en) * | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| US20070048285A1 (en) * | 2005-08-24 | 2007-03-01 | Christopher Baum | Self-inactivating retroviral vector |
| CN102443604B (zh) * | 2011-11-25 | 2014-12-31 | 上海市儿童医院 | 一种安全性慢病毒载体及其应用 |
-
2013
- 2013-10-16 GB GBGB1318347.0A patent/GB201318347D0/en not_active Ceased
-
2014
- 2014-10-16 CN CN201480057140.0A patent/CN105705645B/zh active Active
- 2014-10-16 EP EP14787036.4A patent/EP3058076B1/en active Active
- 2014-10-16 WO PCT/GB2014/053102 patent/WO2015056014A1/en not_active Ceased
- 2014-10-16 ES ES14787036T patent/ES2759049T3/es active Active
- 2014-10-16 JP JP2016524423A patent/JP6525986B2/ja active Active
- 2014-10-16 US US15/029,898 patent/US10184136B2/en active Active